- Home
- CGC vs ENGN Comparison
CGC vs ENGN Comparison
Compare CGC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- ENGN
- Stock Information
- Founded
- CGC N/A
- ENGN 1999
- Country
- CGC Canada
- ENGN Canada
- Employees
- CGC N/A
- ENGN N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- ENGN
- Sector
- CGC Health Care
- ENGN
- Exchange
- CGC Nasdaq
- ENGN Nasdaq
- Market Cap
- CGC 431.7M
- ENGN 349.1M
- IPO Year
- CGC N/A
- ENGN N/A
- Fundamental
- Price
- CGC $1.37
- ENGN $7.75
- Analyst Decision
- CGC Hold
- ENGN Buy
- Analyst Count
- CGC 1
- ENGN 7
- Target Price
- CGC N/A
- ENGN $20.29
- AVG Volume (30 Days)
- CGC 23.8M
- ENGN 262.4K
- Earning Date
- CGC 11-07-2025
- ENGN 09-11-2025
- Dividend Yield
- CGC N/A
- ENGN N/A
- EPS Growth
- CGC N/A
- ENGN N/A
- EPS
- CGC N/A
- ENGN N/A
- Revenue
- CGC $201,572,742.00
- ENGN N/A
- Revenue This Year
- CGC $13.24
- ENGN N/A
- Revenue Next Year
- CGC $3.68
- ENGN N/A
- P/E Ratio
- CGC N/A
- ENGN N/A
- Revenue Growth
- CGC N/A
- ENGN N/A
- 52 Week Low
- CGC $0.77
- ENGN $2.65
- 52 Week High
- CGC $5.80
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- CGC 48.83
- ENGN 71.29
- Support Level
- CGC $1.32
- ENGN $6.07
- Resistance Level
- CGC $1.46
- ENGN $8.35
- Average True Range (ATR)
- CGC 0.11
- ENGN 0.59
- MACD
- CGC -0.00
- ENGN 0.07
- Stochastic Oscillator
- CGC 23.53
- ENGN 75.26
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.